Brokerages Set KindlyMD, Inc. (NASDAQ:NAKA) Target Price at $19.33

Shares of KindlyMD, Inc. (NASDAQ:NAKA) have been given an average rating of “Hold” by the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $19.3333.

Several equities analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. B. Riley Financial raised their price target on KindlyMD from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. TD Cowen boosted their price objective on KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a report on Monday, July 27th. Finally, Wall Street Zen raised KindlyMD to a “sell” rating in a research report on Saturday, May 23rd.

KindlyMD Price Performance

Shares of NAKA opened at $7.98 on Monday. The firm has a market cap of $142.84 million, a P/E ratio of -0.22 and a beta of 15.99. The company has a 50 day simple moving average of $5.45 and a two-hundred day simple moving average of $6.86. KindlyMD has a 1 year low of $3.33 and a 1 year high of $240.00.

KindlyMD (NASDAQ:NAKA) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. The firm had revenue of $35.87 million for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%. On average, sell-side analysts anticipate that KindlyMD will post -12.87 earnings per share for the current year.

Insider Activity

In related news, CEO David F. Bailey purchased 4,852 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were purchased at an average cost of $6.27 per share, for a total transaction of $30,422.04. Following the completion of the acquisition, the chief executive officer owned 3,185,246 shares in the company, valued at approximately $19,971,492.42. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have acquired 41,904 shares of company stock worth $235,231 over the last ninety days. 24.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On KindlyMD

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. purchased a new stake in KindlyMD in the 2nd quarter valued at about $215,000. Geode Capital Management LLC increased its position in shares of KindlyMD by 76.2% during the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock worth $484,000 after acquiring an additional 8,386 shares during the period. Tower Research Capital LLC TRC increased its position in shares of KindlyMD by 1,638.4% during the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock worth $827,000 after acquiring an additional 31,245 shares during the period. Victory Capital Management Inc. bought a new stake in shares of KindlyMD during the third quarter valued at approximately $1,007,000. Finally, Vident Advisory LLC bought a new stake in shares of KindlyMD during the third quarter valued at approximately $2,092,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.